Alteogen saw the highest growth of 0.99% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Alteogen’s patent filings and grants. Buy the databook here.
Alteogen has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 100% of filings. The Australia(AU), and United States(US) patent Office are among the top ten patent offices where Alteogen is filings its patents. Among the top granted patent authorities, Alteogen has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Alteogen
Patents related to rare diseases lead Alteogen's portfolio
Alteogen has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Prader-willi syndrome (pws) related patents lead Alteogen portfolio followed by renal insufficiency, and idiopathic short stature
Alteogen has highest number of patents in prader-willi syndrome (pws) followed by renal insufficiency, idiopathic short stature, acromegaly, and gigantism.
For comprehensive analysis of Alteogen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.